Figure 2
The optimum dose of MHP1-AcN inhibited the development of IMQ-induced skin lesions and inflammatory infiltrates in skin. MHP1-AcN (100 µg/mouse) or saline was systemically administered by daily subcutaneous injection at a distant site from IMQ application. (A) Dorsal skin erythema and scales were recorded and measured on a four-point scale (0 = none; 1 = slight; 2 = moderate; 3 = marked; and 4 = very marked). Dorsal skin thickness was measured using a digital caliper and calculated as the percentage change from baseline. (B) Representative H&E-stained section of dorsal skin. Scale bar: 100 μm. The white rectangular area in the left lower corner in each staining shows a magnified image of the corresponding area. (C) Thickness was calculated as the area of epidermis (µm2)/the length of the basement membrane (µm) in more than 10 fields. Inflammatory infiltrate in the dermis was quantified and shown as the number of infiltrated cells/(0.03 mm2). **P < 0.01 vs. the saline-treated IMQ group. N = 3 per normal group; N = 4 per saline-treated IMQ group; N = 4 per MHP1-AcN-treated IMQ group. All values are expressed as the mean with SEM.
